Condition
Advanced Non-squamous Non-small-cell Lung Cancer
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 9 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
9 shownEfficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerNCT06463665 · 2024-09-26
RECRUITINGJAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C MutationNCT06416410 · 2024-08-07
RECRUITINGEmulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records DatabasesNCT07485166 · 2026-03-12
ACTIVE_NOT_RECRUITINGA First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or AmplificationNCT06585488 · 2024-12-13
TERMINATEDEfficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC PatientsNCT06028633 · 2023-10-01
NOT_YET_RECRUITINGA Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLCNCT04959981 · 2021-09-02
COMPLETEDA Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLCNCT04416035 · 2020-08-17
UNKNOWNPemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based RegimenNCT03792503 · 2019-02-01
WITHDRAWNEfficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer PatientsNCT03190239 · 2017-07-15
WITHDRAWNCommon interventions
PemetrexedDRUG3ApatinibDRUG2CarboplatinDRUG2TislelizumabDRUG2albumin-bound paclitaxelDRUG1BGB-53038DRUG1CetuximabDRUG1China-approved BevacizumabBIOLOGICAL1DocetaxelDRUG1ERAS-007DRUG1ERAS-601DRUG1Initiation of docetaxelDRUG1Initiation of nivolumabDRUG1JAB-21822DRUG1JAB-3312DRUG1lenvatinibDRUG1Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLCDRUG1Olvimulogene nanivacirepvecBIOLOGICAL1OsimertinibDRUG1PaclitaxelDRUG1pembrolizumabDRUG1Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumabDRUG1Platinum chemotherapy: carboplatin or cisplatinDRUG1SotorasibDRUG1TRS003BIOLOGICAL1
Leading sponsors
Trial status mix
RECRUITING2
WITHDRAWN2
ACTIVE_NOT_RECRUITING1
COMPLETED1
NOT_YET_RECRUITING1
TERMINATED1
UNKNOWN1
Phase mix
PHASE23
PHASE12
PHASE32
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.